Some interesting oncology results:
Millennium‘s Velcade used in combo therapy for multiple myeloma shows impressive results.
Cephalon‘s Treanda shows impressive remission numbers for CLL, and effectiveness in non-Hodgins lymphoma (NHL).
Celgene‘s Revlimid continues to produce good results at a low-dose regimen.
Novartis‘ Gleevec: effective at halting leukemia progression up to 6 years.
Eisai decides to grab MGI Pharma, and its stable of oncology drugs.
Biogen-Idec‘s Zevalin, a radioimmunotherapy agent, halted NHL progression in 76% of patients (single treatment!).
AZ’s Arimidex shown superior to tamoxifen for breast cancer, even 4 years after treatment.
GSK‘s Tykerb helps fight brain tumors in combo with Xeloda.
And, on the bleeding edge:
Prasugrel (new blood thinning treatment from Daiichi-Sankyo and Lilly) continues to show promise – and some mixed results in certain populations.
Glaxo‘s experimental platelet booster shows efficacy in long-term treatment (Glaxo also announced new deals with 2 biotechs). However, GSK is now hit with a delay on its Cervarix vaccine.
Bayer and J&J’s experimental blood thinner takes on market-leader Lovenox in blood clot prevention study.
WSJ has summary article on the blood thinner race to market.
And, in other news:
Novartis the latest to announce major job cuts.
Merck still developing obesity and cholesterol drugs.
FDA approves new blood pressure drug from Mylan/Forest.
Changing endpoints…a clinical study no-no. WSJ has the story, on a long-delayed Vytorin study.
Is Alzheimer’s a form of diabetes? Very intriguing line of research…
Leave a Reply